Provided by Tiger Trade Technology Pte. Ltd.

Tarsus Pharmaceuticals, Inc.

78.11
-1.8400-2.30%
Volume:238.12K
Turnover:18.72M
Market Cap:3.43B
PE:-72.16
High:80.01
Open:80.01
Low:77.89
Close:79.95
52wk High:91.53
52wk Low:48.76
Shares:43.88M
Float Shares:35.64M
Volume Ratio:0.41
T/O Rate:0.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0824
EPS(LYR):-1.5900
ROE:-13.68%
ROA:-5.48%
PB:9.89
PE(LYR):-49.13

Loading ...

Tarsus Pharmaceuticals announces $125M private placement

TIPRANKS
·
Aug 06

Tarsus Pharmaceuticals Q2 Sales Beat Estimates, Lifts 2026 Xdemvy Sales Outlook

Reuters
·
Aug 06

Tarsus to Buy Alkeus in Deal Worth About $450 Million Upfront

Reuters
·
Aug 06

Tarsus Prices USD 125 Million PIPE at USD 56 Per Share

Reuters
·
Aug 06

Tarsus Q2 FY26 Net Loss Narrows 8.77% to $18.55 Million; Net Product Sales Rise More than 69% to $173.91 Million

Reuters
·
Aug 06

Tarsus Pharmaceuticals Q2 EPS USD -0.43

THOMSON REUTERS
·
Aug 06

Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth

THOMSON REUTERS
·
Aug 06

Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing

THOMSON REUTERS
·
Aug 06

Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position

THOMSON REUTERS
·
Aug 06

Tarsus Pharmaceuticals, - up to $350 Mln in Milestone Payments upon Regulatory Approval and First Sale

THOMSON REUTERS
·
Aug 06

Tarsus Pharmaceuticals, - Deal Includes $450 Mln Upfront, $270 Mln Cash, $180 Mln in Tarsus Stock

THOMSON REUTERS
·
Aug 06

Tarsus Pharmaceuticals to Report Q2 2026 Results, Host Webcast

Reuters
·
Aug 06

Tarsus Pharmaceuticals is Maintained at Outperform by Mizuho

Dow Jones
·
Aug 01

Mizuho Trims Price Target on Tarsus Pharmaceuticals to $98 From $100, Keeps Outperform Rating

MT Newswires Live
·
Jul 31

Tarsus Pharmaceuticals Inc : Mizuho Cuts Target Price to $98 from $100

THOMSON REUTERS
·
Jul 31

Oppenheimer Sticks to Their Buy Rating for Tarsus Pharmaceuticals (TARS)

TIPRANKS
·
Jul 22

Tarsus Pharmaceuticals is Maintained at Buy by Guggenheim

Dow Jones
·
Jul 21

Rxsight Names Aziz Mottiwala CEO, Ron Kurtz to Become Chief Medical Officer

Reuters
·
Jul 16

Tarsus Pharmaceuticals Announces Chief Commercial Officer Transition

TIPRANKS
·
Jul 14

Tarsus Pharmaceuticals chief commercial officer Aziz Mottiwala to depart

TIPRANKS
·
Jul 14